Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pelthos Therapeutics (PTHS) FCF Margin (2024 - 2025)

Pelthos Therapeutics has reported FCF Margin over the past 2 years, most recently at 37.89% for Q4 2025.

  • Quarterly results put FCF Margin at 37.89% for Q4 2025, down 18210.0% from a year ago — trailing twelve months through Dec 2025 was 94.51% (down 550456.0% YoY), and the annual figure for FY2025 was 135.09%, changed.
  • FCF Margin for Q4 2025 was 37.89% at Pelthos Therapeutics, up from 206.03% in the prior quarter.
  • Over the last five years, FCF Margin for PTHS hit a ceiling of 34808.7% in Q1 2025 and a floor of 83708.96% in Q2 2024.